| Date |
Company |
Amount |
Funding type |
Investors |
Therapeutic area |
Type of Information |
| 2012-12-14 |
AxoGlia Therapeutics (Luxembourg) |
undisclosed |
grant |
The Michael J. Fox Foundation - MJFF (USA) |
Neurodegenerative diseases |
Grant |
| 2012-12-12 |
Biocartis (Belgium) |
€ 34.5 million |
Series D financing round |
PMV (Belgium) RMM Valiance (UK) Debiopharm Group (Switzerland) Korys (investment holding of the Colruyt family) Philips (The Netherlands) Johnson & Johnson Development Corporation - JJDC (USA) the family office of Dr Paul Janssen, Luc Verelst, Benauca, Rudi Pauwels, founder of Biocartis, New Rhein Healthcare (USA) |
Cancer - Oncology |
Fundraising |
| 2012-12-11 |
Oramed Pharmaceuticals (Israel) |
$5.6 Million (€4.3 million) |
private placement |
|
Metabolic diseases |
Private placement |
| 2012-12-10 |
Bicycle Therapeutics (UK) |
£3.75 million (€ 4.6 million) |
equity financing |
Atlas Venture (USA) Novartis Venture Fund (Switzerland) SR One (UK) SV Life Sciences (UK - USA) Astellas Venture Management (Japan) |
|
Fundraising |
| 2012-12-07 |
Epistem (UK) |
£ 4.3 million (€ 5.3 million) |
placement of new ordinary shares |
|
Diagnostic |
Private placement |
| 2012-12-06 |
RedHill Biopharma (Israel) |
$6.5 Million (€5 million) |
financing round |
Company directors Mr. Dan Suesskind (Teva Pharmaceuticals\' former CFO) Dr. Shmuel Cabilly (inventor of the \ |
Autoimmune diseases - Inflammatory diseases - Infectious diseases |
Fundraising |
| 2012-11-26 |
Lanthio Pharma (The Netherlands) |
€4.8 million |
series A financing round |
Morphosys (Germany) BioGeneration Ventures (The Netherlands) INKEF Capital (The Netherlands) Hanzepoort |
|
Fundraising |
| 2012-11-26 |
TxCell (France) |
€12.4 million |
financing round |
InnoBio (France) Auriga Partners (France) Seventure Partners (France) |
Autoimmune diseases - Inflammatory diseases |
Fundraising |
| 2012-11-20 |
Kiadis Pharma (The Netherlands) |
€ 10 million |
equity financing round |
LSP (Life Sciences Partners) (The Netherlands)nDFJ-Esprit (UK) Alta Partners (USA) Quest for Growth (Belgium) NOM (The Netherlands) |
Cancer - Oncology - Transplantation |
Fundraising |
| 2012-11-19 |
Keddem Bioscience, wholly owned subsidiary of Compugen (Israel) |
$15 million |
financing round |
private U.S.-based investment company |
|
Fundraising |
| 2012-11-12 |
Avexxin (Norway) |
|
series B financing round |
Sarsia Seed, Leiv Eiriksson Nyskaping |
Inflammatory diseases |
Fundraising |
| 2012-11-08 |
Lophius Biosciences (Germany) |
140K€ |
grant |
ZIM (Zentrales Innovationsprogramm Mittelstand)-solo-program (Germany) |
Infectious diseases |
Grant |
| 2012-11-06 |
Exonhit (France) |
€ 4.4 million |
private placement |
|
|
Private placement |
| 2012-11-06 |
Arecor (UK) |
£785,000 (€ 984 500) |
grant |
Biomedical Catalyst Fund (UK) |
|
Grant |
| 2012-11-05 |
Life Science Entrepreneurs (Spain) |
|
|
undisclosed private investors from Barcelona, Geneva and Basel, all active in medical applications of life sciences |
|
Fundraising |
| 2012-11-05 |
Pharminox (UK) |
£0.5 million (€0.6 million) |
grant |
Biomedical Catalyst Fund (UK)
|
Cancer - Oncology |
Grant |
| 2012-11-05 |
Ziarco (UK) |
undisclosed |
series A financing round |
Biotechnology Value Fund L.P. (USA) and other affiliates of BVF Partners L.P. (USA) - Pfizer Venture Investments (USA) |
|
Fundraising |
| 2012-11-05 |
Creabilis (Luxembourg) |
£1.42 million (€1.78 million) |
grant |
Biomedical Catalyst Fund (UK) |
Dermatological diseases |
Grant |
| 2012-11-05 |
Cyclaced Pharmaceuticals (USA) |
£1.2 million (€ 1.5 million) |
grant |
Biomedical Catalyst Fund (UK) |
Cancer - Oncology |
Grant |
| 2012-11-05 |
Glide Pharma (UK) |
£2.3 Million (€ 2.88 million) |
grant |
Biomedical Catalyst Fund (UK) |
Bone diseases |
Grant |
